VX-548 is under clinical development by Vertex Pharmaceuticals and currently in Phase II for Diabetic Peripheral Neuropathy. According to GlobalData, Phase II drugs for Diabetic Peripheral Neuropathy have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VX-548’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VX-548 is under development for the treatment of post-operative pain (acute pain), diabetic peripheral neuropathy and neuropathic pain. The drug candidates act by targeting sodium channel protein type 10 subunit alpha.
Vertex Pharmaceuticals overview
Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.
For a complete picture of VX-548’s drug-specific PTSR and LoA scores, buy the report here.